Thank you to our sponsors!
Thank you to those who joined us this week at the 2020 NYBIO Virtual Annual Meeting. On Tuesday, hundreds gathered to join in timely conversations about COVID-19, vaccines, as well as policy and innovation. On Wednesday, we heard a fireside chat between Dr. Michelle McMurry-Heath, CEO of BIO and Dr. Jeremy Levin, CEO of Ovid, and had great discussions about the current state of real world evidence and digital therapeutics.
NewYorkBIO attendees had the chance to network each evening during a digital reception - which worked well to allow new introductions and the renewal of old friendships.
Please join us for our upcoming Virtual Breakfast Series Webinars, every Tuesday morning at 9:00am. We host a guest each week with a unique story, interesting perspective, or experience with think you'll find interesting. Follow us on Twitter @NewYorkBIO.
We hope you'll join us!
|
|
|
NewYorkBIO's Virtual Breakfast Series
Tuesday, September 22nd, 9:00am
|
|
|
|
David Sable, MD
David Sable MD directs healthcare and life science investing for the Special Situations Funds and is portfolio manager for the Special Situations Life Sciences Fund and Life Sciences Innovation Venture Capital funds.
|
|
After graduating from the Wharton School and the University of Pennsylvania School of Medicine, Dr. Sable trained in obstetrics and gynecology at New York Hospital - Cornell Medical Center, and in reproductive endocrinology at the Brigham and Women's Hospital. He co-founded and served as director of the Institute for Reproductive Medicine and Science at Saint Barnabas Medical Center in New Jersey, was founder of Assisted Reproductive Medical Technologies, which was acquired by Saint Barnabas in 1999, and co-founder of Reprogenetics, acquired by Cooper Surgical in 2015. After leaving clinical medicine, Dr. Sable managed a proprietary healthcare portfolio at Deutsche Bank before joining the Special Situations Funds.
Dr. Sable is an adjunct in the department of biology at Columbia University, and teaches “Entrepreneurship in Biotechnology” at Columbia’s Graduate School of Arts and Sciences. He serves on the board of directors for Hamilton Thorne Ltd, MedAnswers Inc, Ohana Biosciences Inc., and Celmatix Inc, and is a clincal advisory board member and board observer for TMRW Life Sciences. He previously served as a board member for Genenews Inc, for the nonprofit advocacy organization RESOLVE, on the medical advisory board for Progyny Inc and on the scientific advisory board of Ovascience Inc. In addition to his academic publications, he has written for the Newark Star-Ledger, Yoga Journal, Xconomy, Genetic Engineering and Biotechnology News, Wharton Magazine, and is a regular contributor to Forbes, covering the reproductive medicine industry.
|
|
Webinar | Virtual Discussions with Genuine Experts
Tuesday, September 22nd, 4:00pm
|
|
|
|
Racing to Beat COVID-19: The Oxford Vaccine and Other Tales from the UK
Speakers: Sir John Bell and President Richard Lifton
History is being made as research institutions, companies, and nations work together to deliver vaccines that we all hope will confer immunity against the novel coronavirus,
|
|
SARS-CoV-2. Sir John Bell, a renowned biomedical scientist at the University of Oxford, is the leader of a rapidly advancing effort within this unprecedented campaign. The vaccine developed at Oxford uses a weakened chimpanzee cold virus combined with SARS-CoV-2 genetic material to elicit a protective immune response. Early results have been encouraging, and just last month, Oxford’s industry partner AstraZeneca and the U.S. government launched a large-scale clinical trial that will be key to the vaccine’s approval. In this webinar, Rockefeller University President Rick Lifton will discuss with Professor Bell the extraordinary challenges involved in the development and international testing of new vaccines amid a global pandemic, as well as other medical measures needed to bring COVID-19 under control. |
|
BIO IMPACT Digital
interactive Ag & Environment Conference
Next week is BIO's IMPACT Digital event. Register and you'll join hundreds of attendees and innovative companies from 25+ countries for a comprehensive education, networking and partnering event – hundreds of hours of value! Plan for two intensive days, September 21-22, to drive your business development for the coming months plus connect and chat live with attendees in our new education and networking platform!
NewYorkBIO Members: use code AF0921220 to access your 25% discount.
|
|
 |
Digital Health Strategy: Leveraging Emerging Technologies in Healthcare
September 25 - October 14
NewYorkBIO Members receive 25% off the registration fee
We are delighted to announce NewYorkBio will be partnering with the Executive Education in the Digital Health Strategy program at Columbia Business School. The Executive Education program will be every Friday from September 25th through October 14th in a virtual, distance learning format.
Together, we can build a more effective healthcare system together.
NewYorkBIO ha will receive 25% off the cost of enrollment. When registering, simply enter “NY Bio” as your middle name.
Click below for more information or schedule an appointment with Program Director Dr. Stan Kachnowski at swk16@gsb.Columbia.edu.
|
|
|
|
Westchester County Business FIRST Grants
Due September 30
$10 Million Grant Program for Business Recovery
This week, the Westchester County Office of Economic Development announced a new $10 million grant program designed to support small businesses and nonprofits facing challenges as a result of the COVID-19 crisis.
Westchester County Business FIRST: Financial Investments for Recovery and a Sustainable Tomorrow – will be accepting applications from September 21 at 10:00 a.m. through September 30, 2020 at midnight. Businesses and nonprofits with 99 or fewer employees may qualify for up to $49,000 to cover expenses such as rent or mortgage payments, employee salaries or benefits, working capital, equipment and other COVID-19-related expenses.
|
|
|
|
BioNJ's BioPartnering Conference
October 6 & 7, 2020
Our friends at BioNJ are hosting their Tenth Annual BioPartnering Conference. Co-sponsored by J.P. Morgan and Johnson & Johnson Innovation, it will bring hundreds of life sciences professionals from the Northeast and beyond together for networking, 1:1 partnering meetings, company presentations, posters, exhibits and plenary sessions. The robust virtual program is designed to foster productive partnerships, create fruitful opportunities, grow the ecosystem and bolster medical innovation.
|
|
BIO Business Solutions Partner
As a NewYorkBIO member, you receive savings and other benefits from our many Member Savings partners including Brex, the Corporate Card for Life Sciences. Just for signing up with Brex you receive 60,000 points value when taken as a statement credit) which helps cover your NewYorkBIO membership fee!
In addition, you receive 3x points on every purchase of lab supplies, which represents a further discount on top of the great discounts you already receive from another NewYorkBIO partner - VWR.
Brex empowers its life sciences customers to spend less time on end of month closes and more time on life changing R&D and is commonly used by young companies for capital preservation and cash management. Other Brex benefits include:
-
No personal guarantee (and no credit check)
-
Rewards tailored specifically for Life Science companies (conference registrations, travel, lab supplies, Apple products)
-
Higher credit limits than traditional cards
-
Seamless integration with various accounting systems including QuickBooks
- No annual fees or foreign fees
|
|
Partnering with BIO to engage biotech in the election |
|
|
|
As you know, the election is fast approaching and so is the deadline to register to vote. In New York, voters must register by October 9th to vote in the November 3rd election. We've partnered with BIO to give you all the information you need to engage. It's important to confirm that you are registered to vote! Use the link below to visit our website with BIO and to learn about your candidates and biotech's policy priorities.
|
|
|
|
|
|
|
